Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension.
CTEPH
DCM
Fibrosis
IPAH
LV hypertrophy
RV-PA coupling
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
01
04
2022
accepted:
19
01
2023
medline:
10
10
2023
pubmed:
16
2
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Fibroblast growth factor 23 (FGF-23) has been associated with left ventricular hypertrophy (LVH) and heart failure. However, its role in right ventricular (RV) remodeling and RV failure is unknown. This study analyzed the utility of FGF-23 as a biomarker of RV function in patients with pulmonary hypertension (PH). In this observational study, FGF-23 was measured in the plasma of patients with PH (n = 627), dilated cardiomyopathy (DCM, n = 59), or LVH with severe aortic stenosis (n = 35). Participants without LV or RV abnormalities served as controls (n = 36). Median FGF-23 plasma levels were higher in PH patients than in healthy controls (p < 0.001). There were no significant differences between PH, DCM, and LVH patients. Analysis across tertiles of FGF-23 levels in PH patients revealed an association between higher FGF-23 levels and higher levels of NT-proBNP and worse renal function. Furthermore, patients in the high-FGF-23 tertile had a higher pulmonary vascular resistance (PVR), mean pulmonary artery pressure, and right atrial pressure and a lower cardiac index (CI) than patients in the low tertile (p < 0.001 for all comparisons). Higher FGF-23 levels were associated with higher RV end-diastolic diameter and lower tricuspid annular plane systolic excursions (TAPSE) and TAPSE/PASP. Receiver operating characteristic analysis revealed FGF-23 as a good predictor of RV maladaptation, defined as TAPSE < 17 mm and CI < 2.5 L/min/m FGF-23 may serve as a biomarker for maladaptive RV remodeling in patients with PH.
Sections du résumé
BACKGROUND
BACKGROUND
Fibroblast growth factor 23 (FGF-23) has been associated with left ventricular hypertrophy (LVH) and heart failure. However, its role in right ventricular (RV) remodeling and RV failure is unknown. This study analyzed the utility of FGF-23 as a biomarker of RV function in patients with pulmonary hypertension (PH).
METHODS
METHODS
In this observational study, FGF-23 was measured in the plasma of patients with PH (n = 627), dilated cardiomyopathy (DCM, n = 59), or LVH with severe aortic stenosis (n = 35). Participants without LV or RV abnormalities served as controls (n = 36).
RESULTS
RESULTS
Median FGF-23 plasma levels were higher in PH patients than in healthy controls (p < 0.001). There were no significant differences between PH, DCM, and LVH patients. Analysis across tertiles of FGF-23 levels in PH patients revealed an association between higher FGF-23 levels and higher levels of NT-proBNP and worse renal function. Furthermore, patients in the high-FGF-23 tertile had a higher pulmonary vascular resistance (PVR), mean pulmonary artery pressure, and right atrial pressure and a lower cardiac index (CI) than patients in the low tertile (p < 0.001 for all comparisons). Higher FGF-23 levels were associated with higher RV end-diastolic diameter and lower tricuspid annular plane systolic excursions (TAPSE) and TAPSE/PASP. Receiver operating characteristic analysis revealed FGF-23 as a good predictor of RV maladaptation, defined as TAPSE < 17 mm and CI < 2.5 L/min/m
CONCLUSION
CONCLUSIONS
FGF-23 may serve as a biomarker for maladaptive RV remodeling in patients with PH.
Identifiants
pubmed: 36790465
doi: 10.1007/s00392-023-02162-y
pii: 10.1007/s00392-023-02162-y
pmc: PMC10562503
doi:
Substances chimiques
Fibroblast Growth Factor-23
7Q7P4S7RRE
Biomarkers
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1382-1393Informations de copyright
© 2023. The Author(s).
Références
Bouzina H, Hesselstrand R, Radegran G (2019) Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension. Pulm Circ 9:2045894019895446. https://doi.org/10.1177/2045894019895446
doi: 10.1177/2045894019895446
pubmed: 31908768
pmcid: 6935881
Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Lechtzin N, Chami H, Girgis RE, Hassoun PM (2011) Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 38:359–367. https://doi.org/10.1183/09031936.00148310
doi: 10.1183/09031936.00148310
pubmed: 21310884
Cojan-Minzat BO, Zlibut A, Agoston-Coldea L (2021) Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Fail Rev 26:1081–1101. https://doi.org/10.1007/s10741-020-09940-0
doi: 10.1007/s10741-020-09940-0
pubmed: 32170530
Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R (2011) Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 45:1239–1247. https://doi.org/10.1165/rcmb.2010-0412OC
doi: 10.1165/rcmb.2010-0412OC
pubmed: 21719795
pmcid: 3361357
Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM (2011) FGF23 induces left ventricular hypertrophy. J Clin Investig 121:4393–4408
doi: 10.1172/JCI46122
pubmed: 21985788
pmcid: 3204831
Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, Jamison EB Jr, Lang RM, Patel AR (2012) Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 14:11. https://doi.org/10.1186/1532-429X-14-11
doi: 10.1186/1532-429X-14-11
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol 69:177. https://doi.org/10.1016/j.rec.2016.01.002
doi: 10.1016/j.rec.2016.01.002
pubmed: 26837729
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstadt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C (2015) Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22:1020–1032. https://doi.org/10.1016/j.cmet.2015.09.002
doi: 10.1016/j.cmet.2015.09.002
pubmed: 26437603
pmcid: 4670583
Gruson D, Lepoutre T, Ketelslegers JM, Cumps J, Ahn SA, Rousseau MF (2012) C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 37:258–262. https://doi.org/10.1016/j.peptides.2012.08.003
doi: 10.1016/j.peptides.2012.08.003
pubmed: 22902597
Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, Temporelli PL, Arena R (2013) Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 305:H1373–H1381. https://doi.org/10.1152/ajpheart.00157.2013
doi: 10.1152/ajpheart.00157.2013
pubmed: 23997100
Han J, Yuan X, Song W, Cheng Y, Lu Y, Zhang Y, Liu Y, Jiang Y (2022) The correlation of fibroblast growth factor 23 with cardiac remodeling in essential hypertension with normal renal function. Cardiology 147:271–280. https://doi.org/10.1159/000524764
doi: 10.1159/000524764
pubmed: 35500559
Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, Xuan W, Liao W, Bin J, Huang X, Kitakaze M, Liao Y (2016) FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget 7:64649–64664. https://doi.org/10.18632/oncotarget.11623
doi: 10.18632/oncotarget.11623
pubmed: 27579618
pmcid: 5323105
Ibe T, Wada H, Sakakura K, Ugata Y, Maki H, Yamamoto K, Seguchi M, Taniguchi Y, Jinnouchi H, Fujita H (2021) Cardiac index predicts long-term outcomes in patients with heart failure. PLoS One 16:e0252833. https://doi.org/10.1371/journal.pone.0252833
doi: 10.1371/journal.pone.0252833
pubmed: 34086818
pmcid: 8177638
Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M (2008) Postprandial mineral metabolism and secondary hyperparathyroidism in Early CKD. J Am Soc Nephrol 19:615–623. https://doi.org/10.1681/asn.2007060673
doi: 10.1681/asn.2007060673
pubmed: 18216315
pmcid: 2391049
Isakova T, Houston J, Santacruz L, Schiavenato E, Somarriba G, Harmon WG, Lipshultz SE, Miller TL, Rusconi PG (2013) Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol 28:2035–2042. https://doi.org/10.1007/s00467-013-2515-7
doi: 10.1007/s00467-013-2515-7
pubmed: 23740037
pmcid: 3755096
Keranov S, Dorr O, Jafari L, Troidl C, Liebetrau C, Kriechbaum S, Keller T, Voss S, Bauer T, Lorenz J, Richter MJ, Tello K, Gall H, Ghofrani HA, Mayer E, Wiedenroth CB, Guth S, Lorchner H, Poling J, Chelladurai P, Pullamsetti SS, Braun T, Seeger W, Hamm CW, Nef H (2021) CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. Eur Respir J. https://doi.org/10.1183/13993003.01192-2019
doi: 10.1183/13993003.01192-2019
pubmed: 33184116
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16:233–270. https://doi.org/10.1093/ehjci/jev014
doi: 10.1093/ehjci/jev014
pubmed: 25712077
Lazzeroni D, Rimoldi O, Camici PG (2016) From left ventricular hypertrophy to dysfunction and failure. Circ J 80:555–564. https://doi.org/10.1253/circj.CJ-16-0062
doi: 10.1253/circj.CJ-16-0062
pubmed: 26853555
Leifheit-Nestler M, Haffner D (2018) Paracrine effects of FGF23 on the heart. Front Endocrinol. https://doi.org/10.3389/fendo.2018.00278
doi: 10.3389/fendo.2018.00278
Miri M, Ahmadi M, Hatami M (2021) Correlation Between fibroblast growth factor-23 and pulmonary arterial hypertension in hemodialysis patients. Iran J Kidney Dis 15:300–305
pubmed: 34279001
Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546–551. https://doi.org/10.1016/j.atherosclerosis.2009.05.013
doi: 10.1016/j.atherosclerosis.2009.05.013
pubmed: 19524924
Naeije R, Manes A (2014) The right ventricle in pulmonary arterial hypertension. Eur Respir Rev Off J Eur Respir Soc 23:476–487. https://doi.org/10.1183/09059180.00007414
doi: 10.1183/09059180.00007414
Niizuma S, Iwanaga Y, Yahata T, Miyazaki S (2017) Renocardiovascular biomarkers: from the perspective of managing chronic kidney disease and cardiovascular disease. Front Cardiovasc Med 4:10–10. https://doi.org/10.3389/fcvm.2017.00010
doi: 10.3389/fcvm.2017.00010
pubmed: 28321399
pmcid: 5337832
Patel CB, DeVore AD, Felker GM, Wojdyla DM, Hernandez AF, Milano CA, O’Connor CM, Rogers JG (2014) Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. Am J Cardiol. https://doi.org/10.1016/j.amjcard.2014.07.022
doi: 10.1016/j.amjcard.2014.07.022
pubmed: 25727083
pmcid: 4253688
Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C, Szekeres T, Horl WH, Strunk G, Vavken P, Pacher R, Hulsmann M (2012) Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Investig 42:649–656. https://doi.org/10.1111/j.1365-2362.2011.02631.x
doi: 10.1111/j.1365-2362.2011.02631.x
Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmuller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS (2013) Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 128(2016–2025):2011–2010. https://doi.org/10.1161/CIRCULATIONAHA.113.001873
doi: 10.1161/CIRCULATIONAHA.113.001873
Rodelo-Haad C, Santamaria R, Muñoz-Castañeda JR, Pendón-Ruiz de Mier MV, Martin-Malo A, Rodriguez M (2019) FGF23, biomarker or target? Toxins 11:175
doi: 10.3390/toxins11030175
pubmed: 30909513
pmcid: 6468608
Roy C, Lejeune S, Slimani A, de Meester C, Ahn As SA, Rousseau MF, Mihaela A, Ginion A, Ferracin B, Pasquet A, Vancraeynest D, Beauloye C, Vanoverschelde J-L, Horman S, Gruson D, Gerber BL, Pouleur A-C (2020) Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail 7:2494–2507. https://doi.org/10.1002/ehf2.12816
doi: 10.1002/ehf2.12816
pubmed: 32578967
pmcid: 7524237
Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB (2010) Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 23:685–713. https://doi.org/10.1016/j.echo.2010.05.010
doi: 10.1016/j.echo.2010.05.010
Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N (2013) Association between circulating fibroblast growth factor 23, alpha-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One 8:e73184. https://doi.org/10.1371/journal.pone.0073184
doi: 10.1371/journal.pone.0073184
pubmed: 24039882
pmcid: 3767778
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res Off J Am Soc Bone Miner Res 19:429–435. https://doi.org/10.1359/JBMR.0301264
doi: 10.1359/JBMR.0301264
Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, Seeger W, Gall H, Richter MJ (2018) Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 266:229–235. https://doi.org/10.1016/j.ijcard.2018.01.053
doi: 10.1016/j.ijcard.2018.01.053
pubmed: 29887454
Tello K, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, Roller F, Seeger W, Wilhelm J, Gall H, Richter MJ (2019) Cardiac magnetic resonance imaging-based right ventricular strain analysis for assessment of coupling and diastolic function in pulmonary hypertension. JACC Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2018.12.032
doi: 10.1016/j.jcmg.2018.12.032
pubmed: 30878422
Trip P, Rain S, Handoko ML, van der Bruggen C, Bogaard HJ, Marcus JT, Boonstra A, Westerhof N, Vonk-Noordegraaf A, de Man FS (2015) Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension. Eur Respir J 45:1603–1612. https://doi.org/10.1183/09031936.00156714
doi: 10.1183/09031936.00156714
pubmed: 25882798
van der Bruggen CEE, Tedford RJ, Handoko ML, van der Velden J, de Man FS (2017) RV pressure overload: from hypertrophy to failure. Cardiovasc Res 113:1423–1432. https://doi.org/10.1093/cvr/cvx145
doi: 10.1093/cvr/cvx145
pubmed: 28957530
Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM (2013) Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 62:D22–D33. https://doi.org/10.1016/j.jacc.2013.10.027
doi: 10.1016/j.jacc.2013.10.027
pubmed: 24355638
Vonk Noordegraaf A, Westerhof BE, Westerhof N (2017) The relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol 69:236–243. https://doi.org/10.1016/j.jacc.2016.10.047
doi: 10.1016/j.jacc.2016.10.047
pubmed: 28081831